Rising Concerns Over Weight Loss Medications in France: Spotlight on Enquête Exclusive

A new episode of *Enquête Exclusive* airing tonight on June 15 will explore the explosive rise of weight loss medications such as Wegovy and Ozempic. With over 30 million adults in the U.S. reportedly having tried these treatments—one in eight adults—the trend is now gaining momentum in France as well.

The medications help users lose an average of 15% of their body weight within a year by mimicking the GLP-1 hormone, which suppresses appetite. Personal success stories are emerging, such as that of Emma, a mother from Georgia, who lost 32 kg and inspired her family to lose over 100 kg collectively. Celebrated figures like Oprah Winfrey and Elon Musk have endorsed these treatments, further igniting public interest.

However, this trend raises serious safety concerns, particularly in the absence of adequate medical oversight. Reports indicate that the use of these drugs is expanding into beauty salons and among people without obesity seeking to prevent weight gain. "The normalization of these treatments is alarming," warns a healthcare specialist, emphasizing the potential health risks involved.

Notably, there have been severe adverse effects linked to these medications. The case of Isabelle Charrier, a French woman who developed stomach paralysis from treatment, is highlighted, leaving her with an incurable condition and substantial weight loss. This type of incident is prompting lawyers in the U.S. to prepare lawsuits against pharmaceutical companies for potential negligence regarding health risks tied to these drugs.

Meanwhile, in France, a burgeoning black market for these medications is noted, with easy access and illegal sales flourishing on social media platforms. Such developments complicate efforts to regulate and monitor the use of these medications. As awareness spreads, *Enquête Exclusive* aims to shed light on whether the allure of effortless weight loss through simple injections is indeed a viable solution or a dangerous gamble.

With rising trends and intensifying scrutiny, the upcoming program seeks to address the complexities surrounding the emergence of weight loss drugs in both America and France, emphasizing the urgent need for caution and due diligence.